Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia

Swati Sikaria, Ibrahim Aldoss, Mojtaba Akhtari

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Adult B-acute lymphoblastic leukemia (B-ALL) does not share the favorable prognosis seen in pediatric patients with the same disease. Less than 50% of patients experience long-term survival and for those adults over age 60, long-term survival is only 10%. At time of relapse, 5-year prognosis is a dismal 7%. Novel and less toxic agents are urgently needed.The last few years have seen a surge in immune therapies for B-ALL. These agents may target CD19, CD20, CD22, and less frequently CD52. Expression of these surface markers and the drugs which target them are discussed. Some immune therapies are simple monoclonal antibodies against B lymphocyte markers such as rituximab, ofatumumab, and epratuzumab. Others are in a class of antibody-drug conjugates which link a highly toxic chemotherapy to a monoclonal antibody for targeted delivery, such as inotuzumab and denintuzumab. Finally, novel immune therapies recruit (in the case of bispecific T cell engager [BiTE]) or modify (in the case of chimeric antigen receptor [CAR] T cells) one's own T cells to fight leukemic cells.This article reviews the rationale, clinical data, and toxicity profiles of immune therapies approved or in late stages of development for B-ALL.

Original languageEnglish (US)
Pages (from-to)113-123
Number of pages11
JournalImmunology Letters
Volume172
DOIs
StatePublished - Apr 1 2016

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Monoclonal Antibodies
Poisons
T-Lymphocytes
Survival
Immunoglobulin Isotypes
Therapeutics
T-Cell Antigen Receptor
Pharmaceutical Preparations
B-Lymphocytes
Pediatrics
Recurrence
Drug Therapy

Keywords

  • Acute lymphoblastic leukemia
  • Immunotherapy
  • Leukemia
  • Monoclonal antibodies

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia. / Sikaria, Swati; Aldoss, Ibrahim; Akhtari, Mojtaba.

In: Immunology Letters, Vol. 172, 01.04.2016, p. 113-123.

Research output: Contribution to journalReview article

Sikaria, Swati ; Aldoss, Ibrahim ; Akhtari, Mojtaba. / Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia. In: Immunology Letters. 2016 ; Vol. 172. pp. 113-123.
@article{ecc268871522487bbbcb20d19aa4df3a,
title = "Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia",
abstract = "Adult B-acute lymphoblastic leukemia (B-ALL) does not share the favorable prognosis seen in pediatric patients with the same disease. Less than 50{\%} of patients experience long-term survival and for those adults over age 60, long-term survival is only 10{\%}. At time of relapse, 5-year prognosis is a dismal 7{\%}. Novel and less toxic agents are urgently needed.The last few years have seen a surge in immune therapies for B-ALL. These agents may target CD19, CD20, CD22, and less frequently CD52. Expression of these surface markers and the drugs which target them are discussed. Some immune therapies are simple monoclonal antibodies against B lymphocyte markers such as rituximab, ofatumumab, and epratuzumab. Others are in a class of antibody-drug conjugates which link a highly toxic chemotherapy to a monoclonal antibody for targeted delivery, such as inotuzumab and denintuzumab. Finally, novel immune therapies recruit (in the case of bispecific T cell engager [BiTE]) or modify (in the case of chimeric antigen receptor [CAR] T cells) one's own T cells to fight leukemic cells.This article reviews the rationale, clinical data, and toxicity profiles of immune therapies approved or in late stages of development for B-ALL.",
keywords = "Acute lymphoblastic leukemia, Immunotherapy, Leukemia, Monoclonal antibodies",
author = "Swati Sikaria and Ibrahim Aldoss and Mojtaba Akhtari",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.imlet.2016.02.014",
language = "English (US)",
volume = "172",
pages = "113--123",
journal = "Immunology Letters",
issn = "0165-2478",
publisher = "Elsevier",

}

TY - JOUR

T1 - Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia

AU - Sikaria, Swati

AU - Aldoss, Ibrahim

AU - Akhtari, Mojtaba

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Adult B-acute lymphoblastic leukemia (B-ALL) does not share the favorable prognosis seen in pediatric patients with the same disease. Less than 50% of patients experience long-term survival and for those adults over age 60, long-term survival is only 10%. At time of relapse, 5-year prognosis is a dismal 7%. Novel and less toxic agents are urgently needed.The last few years have seen a surge in immune therapies for B-ALL. These agents may target CD19, CD20, CD22, and less frequently CD52. Expression of these surface markers and the drugs which target them are discussed. Some immune therapies are simple monoclonal antibodies against B lymphocyte markers such as rituximab, ofatumumab, and epratuzumab. Others are in a class of antibody-drug conjugates which link a highly toxic chemotherapy to a monoclonal antibody for targeted delivery, such as inotuzumab and denintuzumab. Finally, novel immune therapies recruit (in the case of bispecific T cell engager [BiTE]) or modify (in the case of chimeric antigen receptor [CAR] T cells) one's own T cells to fight leukemic cells.This article reviews the rationale, clinical data, and toxicity profiles of immune therapies approved or in late stages of development for B-ALL.

AB - Adult B-acute lymphoblastic leukemia (B-ALL) does not share the favorable prognosis seen in pediatric patients with the same disease. Less than 50% of patients experience long-term survival and for those adults over age 60, long-term survival is only 10%. At time of relapse, 5-year prognosis is a dismal 7%. Novel and less toxic agents are urgently needed.The last few years have seen a surge in immune therapies for B-ALL. These agents may target CD19, CD20, CD22, and less frequently CD52. Expression of these surface markers and the drugs which target them are discussed. Some immune therapies are simple monoclonal antibodies against B lymphocyte markers such as rituximab, ofatumumab, and epratuzumab. Others are in a class of antibody-drug conjugates which link a highly toxic chemotherapy to a monoclonal antibody for targeted delivery, such as inotuzumab and denintuzumab. Finally, novel immune therapies recruit (in the case of bispecific T cell engager [BiTE]) or modify (in the case of chimeric antigen receptor [CAR] T cells) one's own T cells to fight leukemic cells.This article reviews the rationale, clinical data, and toxicity profiles of immune therapies approved or in late stages of development for B-ALL.

KW - Acute lymphoblastic leukemia

KW - Immunotherapy

KW - Leukemia

KW - Monoclonal antibodies

UR - http://www.scopus.com/inward/record.url?scp=84960408565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960408565&partnerID=8YFLogxK

U2 - 10.1016/j.imlet.2016.02.014

DO - 10.1016/j.imlet.2016.02.014

M3 - Review article

C2 - 26921100

AN - SCOPUS:84960408565

VL - 172

SP - 113

EP - 123

JO - Immunology Letters

JF - Immunology Letters

SN - 0165-2478

ER -